CDR101, targeting CD3, BCMA, and PD-L1, could guide T cells to BCMA-expressed tumor cells and play a role in combating immunosuppression caused by the interaction of PD-L1 and PD-1 at the immune synapse site, which may reduce the possibility of “on-target off-tumor” effects. This evidence concerns the gene CD274 and neoplasm.